Loading clinical trials...

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects | Clinical Trials | Clareo Health

TERMINATEDPHASE1

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

A Comparison of the Bioavailability of Rifabutin With and Without Lopinavir/Ritonavir in Healthy Adult Subjects

NCT00743470•Abbott

View on ClinicalTrials.gov

Summary

The purpose of this study is to study the safety, tolerability and pharmacokinetics of rifabutin dosing with lopinavir/ritonavir tablets in healthy volunteers.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adult Male or Female 18-55 yrs.
•Subject has provided written consent.
•Subject is in general good health.
•If female, subject is postmenopausal.
•If female, subject is not pregnant and is not breast-feeding.
•Subject must use birth control methods or be surgically sterile.

Exclusion Criteria

•Subject is HAV-IgM, HBsAg or HIV Ab positive.
•Positive screen for drugs of abuse, alcohol, or smoking.
•Cannot be on any medication, including over the counter drugs.
•Cannot have previous history of alcohol or drug abuse.
•Cannot have history of any major diseases or disorders.

Locations (1)

Site Reference ID/Investigator# 11441

Waukegan, Illinois, United States

Key Dates

Start Date

August 1, 2008

Primary Completion Date

October 1, 2008

Last Updated

November 2, 2010

Enrollment

ACTUAL participants

Conditions

HIVTuberculosis

Interventions

lopinavir/ritonavir

DRUG

rifabutin

DRUG

Thinking and Memory Problems in People With HIV

NCT01875588

HIV Positive

View study

RECRUITINGPHASE2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 2, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

Inclusion Criteria

Exclusion Criteria

Thinking and Memory Problems in People With HIV

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs